Translational cancer research · 2020
Association of CMYC polymorphisms with hepatoblastoma risk.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Tianyou, Wen Yang, Li Jiahao, Tan Tianbao, Yang Jiliang, Pan Jing, Hu Chao, Yao Yuxiao, Zhang Jiao, Li Suhong, Xia Huimin, He Jing, Zou Yan
Аннотация
BACKGROUND: Single-nucleotide polymorphisms (SNPs) in genes may affect gene expression and contribute to cancer susceptibility. This study aimed to explore the association between CMYC gene polymorphisms and hepatoblastoma risk.
METHODS: Hepatoblastoma patients and cancer-free controls were recruited and matched by age and sex. Genotypes were determined by TaqMan, and the strength of the association of interest was determined by calculating odds ratios (ORs) and 95% confidence intervals (CIs). The distributions of various CMYC genotypes among subjects were recorded, followed by analyses of associations between CMYC polymorphisms and hepatoblastoma risk.
RESULTS: A total of 213 hepatoblastoma patients and 958 cancer-free controls were enrolled. No significant associations between the CMYC rs4645943 and rs2070583 polymorphisms and hepatoblastoma risk were found (all P>0.05). In stratification analysis based on age, sex, and clinical stage, the CMYC rs4645943 and rs2070583 polymorphisms were not associated with hepatoblastoma susceptibility (all P>0.05).
CONCLUSIONS: Thus, the CMYC rs4645943 and rs2070583 polymorphisms were not associated with hepatoblastoma risk in the study cohort.
METHODS: Hepatoblastoma patients and cancer-free controls were recruited and matched by age and sex. Genotypes were determined by TaqMan, and the strength of the association of interest was determined by calculating odds ratios (ORs) and 95% confidence intervals (CIs). The distributions of various CMYC genotypes among subjects were recorded, followed by analyses of associations between CMYC polymorphisms and hepatoblastoma risk.
RESULTS: A total of 213 hepatoblastoma patients and 958 cancer-free controls were enrolled. No significant associations between the CMYC rs4645943 and rs2070583 polymorphisms and hepatoblastoma risk were found (all P>0.05). In stratification analysis based on age, sex, and clinical stage, the CMYC rs4645943 and rs2070583 polymorphisms were not associated with hepatoblastoma susceptibility (all P>0.05).
CONCLUSIONS: Thus, the CMYC rs4645943 and rs2070583 polymorphisms were not associated with hepatoblastoma risk in the study cohort.